For instance, CD-55 and CD-59 are crucial complement regulatory proteins elevated in various cancers, while Carcino-embryonic antigen (CEA) is a highly specific cancer biomarker, whose targeted immunotherapies are still in the early clinical trials (11). The gene discussed is CD59; the disease is cancer.